rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.
|
29371951 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Doxycyclin-inducible knockdown of endogenous B-Raf(V600E) decreases cellular motility and invasion in conventional and three-dimensional (3D) culture, whereas it promotes cell-cell contacts and induces various hallmarks of differentiated epithelia.
|
25381152 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, statistically significant correlations of BRAF(V600E) with indicators of tumor aggressiveness such as thyroid capsular invasion, multifocality, lymph node metastasis, and extrathyroidal spread were found.
|
22426956 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.
|
27210749 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, over-expression of (V600E)BRAF increases migration and invasion of wild-type BRAF thyroid cells.
|
23435375 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we report that guanosine monophosphate synthase (GMPS), an enzyme required for the de novo biosynthesis of GMP, has a major role in invasion and tumorigenicity of cells derived from either BRAF(V600E) or NRAS(Q61R) human metastatic melanomas.
|
25909885 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .039), showed increased extrathyroidal invasion (38.8% vs 14.7%, P = .017) and lymph node metastasis (71.4% vs 48.4%, P = .038), and received more radioactive iodine therapy (79.2% vs 52.9%, P = .012) than the mixed BRAF(V600E) mutation group.
|
24612623 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The association between BRAF((V600E)) and extra-thyroid invasion</span> was also found in micro-PTCs (P=0.006).
|
18310287 |
2008 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis.
|
22767446 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT.Similar results were confirmed in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism.
|
27880942 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In functional experiments, Nthy/V600E showed increased anchorage-independent growth and invasion through Matrigel, compared to Nthy/WT.
|
28031237 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
OCCLs were evaluated in terms of proliferation, migration, invasion and BRAF V600E point mutation assays.
|
29291435 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data indicate that BRAF(V600E) is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion.
|
19355825 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One-hundred and twenty-nine papillary thyroid microcarcinomas were tested for BRAF(V600E) mutation by single-strand conformation polymorphism, and their clinicopathologic features (age, sex, tumor size, multifocality, nodal metastases, histologic subtype, tumor cell morphology, architecture, tumor-associated stromal reaction, tumor interface to non-neoplastic thyroid (well circumscribed vs infiltrative), extrathyroidal extension, lymphovascular invasion, intratumoral multinucleated giant cells, and adjacent non-neoplastic thyroid pathology) were examined.
|
22918165 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was significantly associated with male sex, tumor size, extrathyroidal invasion, nodal metastasis, and advanced tumor stage (p < .05).
|
22488961 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis.
|
21447745 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Doxycyclin-inducible knockdown of endogenous B-Raf(V600E) decreases cellular motility and invasion in conventional and three-dimensional (3D) culture, whereas it promotes cell-cell contacts and induces various hallmarks of differentiated epithelia.
|
25381152 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.
|
29371951 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p < 0.001), and an advanced stage (p = 0.019).
|
28004221 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There was no significant association between BRAF(V600E) mutation and sex, histologic type, the Clark level, the Breslow index, solar elastosis, angiolymphatic and perineural invasion, satellitosis, and coexisting nevus.
|
24471189 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF (V600E) causes upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1), which promotes cell invasion in papillary thyroid carcinoma (PTC).
|
23893334 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT.Similar results were confirmed in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism.
|
27880942 |
2017 |